Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Seattle Children'S Hospital D/B/A Seattle Children'S Research Institute has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 7 distinct examiners and 5 distinct art units, indicating broad examiner distribution within a narrower set of technical groups.
SPENCE, JENNIFER SUZANNE is the busiest listed examiner, with 1 pending matter. Counsel should coordinate technology descriptions and disclosure positions across the five art units while preparing examiner-specific responses.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §103 only | 1 (14%) |
| Multi-statute (no §101) | 3 (43%) |
| No statute on record | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
| O'BRIEN, LEA S | 1 | 51.4% | +13.9% |
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
| KUDO, KEN | 1 | — | — |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
| FRITCHMAN, REBECCA M | 1 | 45.6% | +35.4% |
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293330 | SYNTHETIC NUCLEIC ACID ELEMENTS FOR ENHANCING CAR T CELL EFFICACY | O'BRIEN, LEA S | — |
| 18560903 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | NICKOL, GARY B | — |
| 18463683 | Processing Images to Associate with Stages of a Surgical Procedure | KUDO, KEN | — |
| 18261656 | HYBRID AND TRUNCATED IMMUNE CELL PROTEINS | CUNNINGCHEN, KATHLEEN MARY | — |
| 18044752 | DIAGNOSTIC METHODS FOR KAWASAKI DISEASE | FRITCHMAN, REBECCA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998206 | CHIMERIC ANTIGEN RECEPTORS (CARS) TARGETING NATURAL KILLER CELLS | BELYAVSKYI, MICHAIL A | 34d |
| 18920747 | RESCUING VOLTAGE-GATED SODIUM CHANNEL FUNCTION IN INHIBITORY NEURONS | SPENCE, JENNIFER SUZANNE | — |
| 18293330 | SYNTHETIC NUCLEIC ACID ELEMENTS FOR ENHANCING CAR T CELL EFFICACY | O'BRIEN, LEA S | — |
| 18560903 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | NICKOL, GARY B | — |
| 18261656 | HYBRID AND TRUNCATED IMMUNE CELL PROTEINS | CUNNINGCHEN, KATHLEEN MARY | — |
| 18044752 | DIAGNOSTIC METHODS FOR KAWASAKI DISEASE | FRITCHMAN, REBECCA M | — |
| Art Unit | Apps |
|---|---|
| 1646 | 2 |
| 1643 | 1 |
| 2671 | 1 |
| 1758 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18920747 | RESCUING VOLTAGE-GATED SODIUM CHANNEL FUNCTION IN INHIBITORY NEURONS | SPENCE, JENNIFER SUZANNE | — | Other | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18293330 | SYNTHETIC NUCLEIC ACID ELEMENTS FOR ENHANCING CAR T CELL EFFICACY | O'BRIEN, LEA S | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Jan 29, 2024 |
| 18560903 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | NICKOL, GARY B | 1643 | §102§112 | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18463683 | Processing Images to Associate with Stages of a Surgical Procedure | KUDO, KEN | 2671 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18261656 | HYBRID AND TRUNCATED IMMUNE CELL PROTEINS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103§112 | Final Rejection | — | Pending | Jul 14, 2023 |
| 18044752 | DIAGNOSTIC METHODS FOR KAWASAKI DISEASE | FRITCHMAN, REBECCA M | 1758 | §101§103§112 | Final Rejection | — | Pending | Mar 09, 2023 |
| 17998206 | CHIMERIC ANTIGEN RECEPTORS (CARS) TARGETING NATURAL KILLER CELLS | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 34d | Pending | Nov 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSeattle Children'S Hospital D/B/A Seattle Children'S Research Institute has 7 pending office actions as of October 2026, spread across 5 art units and 7 examiners.
Jennifer Suzanne Spence has the most, with 1 of Seattle Children'S Hospital D/B/A Seattle Children'S Research Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
